Status:
RECRUITING
Effect of Questionnaires and Feedback on the Patient Compliance for Endoscopic Surveillance After ESD
Lead Sponsor:
Xijing Hospital of Digestive Diseases
Conditions:
Patient Compliance
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Endoscopic submucosal dissection (ESD) is now considered the standard treatment for early gastrointestinal neoplasms. However, there is still a possibility of developing local recurrence or metachrono...
Detailed Description
This is a prospective, randomized controlled, superiority trial. The study population consists of patients after ESD for mucosal lesions at Xijing Hospital. In the control arm, patients after ESD are ...
Eligibility Criteria
Inclusion
- Adult patients (≥18 years) after ESD for mucosal lesions.
Exclusion
- Patients after ESD for submucosal tumors, e.g. stromal tumors, neuroendocrine tumors;
- Additional radical surgery after ESD procedure;
- Past history of ESD procedure or local recurrence;
- Severe comorbidities with a life expectancy of \<6 months as judged by the investigator;
- Unable to cooperate with information collection due to mental disorders, severe neurosis, or dysgnosia;
- Unable to understand or unwilling to sign a written informed consent.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2029
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06092281
Start Date
October 1 2023
End Date
December 1 2029
Last Update
April 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital of Digestive Disease
Xi'an, Shaanxi, China, 710032